Expression and prognosis of inducible T‐cell co‐stimulator and its ligand in Chinese stage I–III lung adenocarcinoma patients
Abstract Background Immunotherapy has become the fastest‐adopting treatment paradigm for lung cancer with improved survival. By binding with its ligand (inducible T‐cell co‐stimulator and its ligand [ICOSL]), an inducible T‐cell co‐stimulator (ICOS) could contribute to reversing immunosuppression an...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | Animal Models and Experimental Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ame2.12355 |